FREQUENCY OF EJACULATORY DISORDERS ASSOCIATED WITH TAMSULOSIN THERAPY IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA

Muhammad A1, Muhammad Salman K1

Research Type

Clinical

Abstract Category

Male Sexual Dysfunction

Abstract 523
Open Discussion ePosters
Scientific Open Discussion Session 104
Thursday 24th October 2024
11:05 - 11:10 (ePoster Station 2)
Exhibition Hall
Benign Prostatic Hyperplasia (BPH) Bladder Outlet Obstruction Sexual Dysfunction
1. Lady Reading Hospital Peshawar Pakistan
Presenter
Links

Poster

Abstract

Hypothesis / aims of study
Benign prostatic hyperplasia (BPH) is very common condition in elderly male. BPH, overactive bladder, urinary tract infection, tumors, stones, or functional problems of the lower  urinary  tract  are  some  of  the  conditions  that  can  cause  LUTS.  α  1-Adrenoceptor antagonists  are  routinely  used  to  treat  BPH,  and  urologists  are  familiar  with  their  safety profiles.It has been noticed that many patients having LUTS due to BPH also experience ED, causing  problems  in  their  sexual  life  but  this  aspect  has  been  ignored  many  times  by urologists, which adds to the patient burden. Despite the good tolerability of this drug, it still has  got  high  chance  of  ED.So  this  study wasdesigned  to  determine  the  frequency  of ejaculatory dysfunction in our population.
Study design, materials and methods
It’s  a  cross  sectional  study  ,  conducted  from   1st   January   2022   to   31 December   2022.All   adult   male   patients presented  to  Urology  OPD  with  Lower Urinary Tract Symptoms  were included  in  the  study.  After  a  detail  history, examination including digital rectal examination  (DRE)  and  investigations  like Urine   routine   examination,   urine   culture, serum    PSA,    renal    function    tests    and Ultrasound  Kidney,  Ureter,  Bladder,  Prostate and  Pre  and  Post  void  residual  urine  the patients    were    advised    alpha    adrenergic blocking  agents  like    Tamsulosin  0.4  mg  OD at  night.  Erectile  dysfunction  was  assessed  of all  patients  before  starting  therapy  and  after two  2  months.  Retrograde  ejaculation  was assessed by taking the history from the patient and   examining   first   voided   urine   after ejaculation  for  sperm. The  data  was  collected in  a  pre-designed  proforma.All  statistical analyzes were performed using SPSS software version 20. Data from the study was analyzed and  compared  using  73  descriptive  statistics (frequency,  percentage,  mean  ±  SD).  Mean and  standard  deviations  were  calculated  for quantitative variables like age, BP, BMI, PSA level, voided urine volume, and residual urine volume.   Frequency   and   percentages   were calculated for erectile dysfunction, ejaculatory dysfunction, and complications of ejaculation. Ejaculatory  dysfunction  was  stratified  against age,  blood  pressure,  BMI,  PSA  level,  voided urine  volume,  residual  urine  volume,  erectile dysfunction,   ejaculatory   dysfunction,   and complications of ejaculation.
Results
Mean  age  of  patients  was  52  years  with  a standard deviation ± 7.28. Mean systolic blood pressure  was  124.83  with  SD  ±.91,  mean diastolic blood pressure was 80 with SD ±.23, mean  BMI  was  28  Kg/m2  with  SD  ±  3.91, Mean prostate-specific antigen was 1.97 ng/dl with  SD  ±3.18,  Mean  voided  urine  volume was   292.75   ml   with   SD   ±150.69,   Mean residual volume was 32.28 ml with SD ±31.28 .The   frequency   of ejaculatory  disorders  and  erectile  dysfunction among 111 patients was analyzed as 72(65%) and 21(19%) respectively . Stratification  of  ejaculatory disorders  and  erectile  dysfunction  concerning age,  blood  pressure,  BMI,  PSA  level,  voided urine  volume,  residual  urine  volume,  erectile dysfunction,  and  complications  of  ejaculation is best described in tables attached.
Interpretation of results
A total  of  111  patients  were  included  in  the  study.  Mean  age  was  52  years  with  a standard  deviation  ±  7.28.  Ejaculatory  disorders  were observed  in  72(65%)  patients while 21(19%) patients had erectile dysfunction. The  total  incidence  of ejaculatory  dysfunction  (EjD)  after  12  weeks of follow  up was  13.4%.  The incidence  of seven  distinct  types  of  ejaculatory  dysphoria (EjD) were found in 2.4%, 3.1%, 3.9%, 3.9%, 6.3%,  7.1%,  and  3.1%  of  cases,  respectively, These   types   of   EjD   include   decreased frequency, delay, increased dryness, decreased strength/force, reduced volume, less pleasure, and pain during ejaculation. IPSS respondents had  higher  baseline  EjFD  scores  than  non-responders  (26.09  vs.  24.06,  P=0.03).  Among IPSS  respondents,  a  decrease  in  EjFDscore occurred  more  frequently.A  smaller  prostate, higher  baseline  MSHQ  totals,  higher  EjFD scores,   and   milder   lower   urinary   tract symptoms  were  associated  with  a  greater incidence of EjD.
Concluding message
The  study  concludes  that  the  frequency  of ejaculatory disorders associated with tamsulosin  therapy  for  BPH  was  65%,  and erectile  dysfunction  was  observed  in  19%  of the patients.
Figure 1 DEMOGRAPHICS AND BASELINE PARAMETERS (n=111)
Figure 2 EJACULATORY DISORDERS AND ERECTILE DYSFUNCTION (n=111)
Figure 3 EJACULATORY COMPLICATIONS (n=72)
Disclosures
Funding non Clinical Trial No Subjects Human Ethics Committee IRB MTI LRH Helsinki Yes Informed Consent Yes
11/05/2025 10:54:04